We successfully standardized and validated OS prognostic assays for low BAALC and high EVI1 expression levels in AML that we integrated into an in vitro diagnostic platform for clinical use that simultaneously detects t(8;21), t(15;17), inv(16), t(16;16), NPM1, and CEBPA double mutations. The gene discussed is NPM1; the disease is acute myeloid leukemia.